Aravindhan Veerapandiyan
Concepts (209)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Muscular Atrophy, Spinal | 4 | 2022 | 12 | 2.320 |
Why?
| Oligonucleotides | 4 | 2020 | 76 | 2.240 |
Why?
| Pneumonia, Viral | 3 | 2020 | 184 | 1.740 |
Why?
| Spastic Paraplegia, Hereditary | 2 | 2022 | 2 | 1.720 |
Why?
| Coronavirus Infections | 3 | 2020 | 192 | 1.710 |
Why?
| Muscular Dystrophy, Duchenne | 2 | 2022 | 16 | 1.580 |
Why?
| Mutation | 12 | 2023 | 1504 | 1.520 |
Why?
| Disease Management | 2 | 2020 | 184 | 1.320 |
Why?
| Dystonic Disorders | 2 | 2023 | 5 | 1.310 |
Why?
| Pandemics | 4 | 2022 | 594 | 1.180 |
Why?
| Spasms, Infantile | 2 | 2018 | 31 | 1.040 |
Why?
| Epilepsy | 2 | 2022 | 191 | 1.000 |
Why?
| Spinal Muscular Atrophies of Childhood | 2 | 2020 | 8 | 0.950 |
Why?
| Peroneal Neuropathies | 2 | 2021 | 4 | 0.940 |
Why?
| Child | 21 | 2023 | 7368 | 0.930 |
Why?
| Intellectual Disability | 2 | 2022 | 150 | 0.920 |
Why?
| Dystonia | 1 | 2023 | 11 | 0.910 |
Why?
| Nerve Tissue Proteins | 2 | 2021 | 200 | 0.850 |
Why?
| Humans | 42 | 2023 | 54391 | 0.840 |
Why?
| Myasthenic Syndromes, Congenital | 1 | 2021 | 6 | 0.820 |
Why?
| Chromosomes, Human, Pair 22 | 2 | 2011 | 42 | 0.780 |
Why?
| Fasciculation | 1 | 2020 | 2 | 0.770 |
Why?
| Isaacs Syndrome | 1 | 2020 | 2 | 0.770 |
Why?
| Hereditary Sensory and Motor Neuropathy | 1 | 2020 | 3 | 0.770 |
Why?
| Seizures | 3 | 2018 | 209 | 0.760 |
Why?
| Muscular Dystrophies | 1 | 2020 | 16 | 0.750 |
Why?
| Myopathies, Structural, Congenital | 1 | 2020 | 11 | 0.750 |
Why?
| Codon, Nonsense | 1 | 2020 | 29 | 0.750 |
Why?
| Anticonvulsants | 2 | 2012 | 129 | 0.740 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2020 | 96 | 0.720 |
Why?
| Charcot-Marie-Tooth Disease | 1 | 2019 | 11 | 0.720 |
Why?
| Glucocorticoids | 3 | 2020 | 234 | 0.720 |
Why?
| Epstein-Barr Virus Infections | 1 | 2020 | 35 | 0.720 |
Why?
| Recombinant Fusion Proteins | 1 | 2020 | 206 | 0.720 |
Why?
| Phenotype | 3 | 2020 | 819 | 0.700 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 208 | 0.690 |
Why?
| Consensus | 1 | 2020 | 157 | 0.690 |
Why?
| Encephalitis | 2 | 2017 | 48 | 0.690 |
Why?
| Multiple Sclerosis | 1 | 2019 | 72 | 0.680 |
Why?
| Male | 26 | 2021 | 27347 | 0.680 |
Why?
| Chromosome Duplication | 1 | 2018 | 7 | 0.670 |
Why?
| Survival of Motor Neuron 1 Protein | 1 | 2018 | 3 | 0.670 |
Why?
| Adolescent | 14 | 2021 | 6900 | 0.660 |
Why?
| Munc18 Proteins | 1 | 2018 | 3 | 0.660 |
Why?
| Infant | 9 | 2020 | 3829 | 0.660 |
Why?
| Microfilament Proteins | 1 | 2018 | 47 | 0.650 |
Why?
| Spinal Puncture | 1 | 2018 | 20 | 0.650 |
Why?
| Epilepsies, Myoclonic | 1 | 2018 | 11 | 0.650 |
Why?
| Attention Deficit Disorder with Hyperactivity | 2 | 2018 | 231 | 0.640 |
Why?
| Head | 1 | 2018 | 78 | 0.630 |
Why?
| Electroencephalography | 6 | 2018 | 357 | 0.630 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 2018 | 113 | 0.620 |
Why?
| Chromosome Deletion | 3 | 2018 | 150 | 0.600 |
Why?
| Central Nervous System Diseases | 1 | 2017 | 30 | 0.600 |
Why?
| DiGeorge Syndrome | 3 | 2012 | 20 | 0.600 |
Why?
| Delivery of Health Care | 1 | 2020 | 325 | 0.590 |
Why?
| Pedigree | 3 | 2022 | 146 | 0.590 |
Why?
| Dystrophin | 2 | 2020 | 6 | 0.580 |
Why?
| Carrier Proteins | 1 | 2018 | 360 | 0.560 |
Why?
| Muscular Diseases | 2 | 2020 | 65 | 0.550 |
Why?
| Child, Preschool | 9 | 2021 | 4158 | 0.510 |
Why?
| Emergency Service, Hospital | 1 | 2018 | 543 | 0.470 |
Why?
| Female | 19 | 2021 | 28471 | 0.470 |
Why?
| Tomography, X-Ray Computed | 1 | 2018 | 1222 | 0.430 |
Why?
| Epilepsy, Complex Partial | 1 | 2012 | 3 | 0.430 |
Why?
| Carbamazepine | 1 | 2012 | 15 | 0.430 |
Why?
| Brain | 2 | 2018 | 1392 | 0.420 |
Why?
| Epilepsy, Tonic-Clonic | 1 | 2011 | 3 | 0.400 |
Why?
| Pyridoxal Phosphate | 1 | 2011 | 10 | 0.400 |
Why?
| Cephalometry | 1 | 2011 | 21 | 0.400 |
Why?
| Myoglobinuria | 1 | 2010 | 3 | 0.390 |
Why?
| Triazines | 1 | 2011 | 30 | 0.390 |
Why?
| Epilepsy, Absence | 1 | 2011 | 11 | 0.390 |
Why?
| Ocular Motility Disorders | 1 | 2011 | 21 | 0.390 |
Why?
| Velopharyngeal Insufficiency | 1 | 2011 | 21 | 0.390 |
Why?
| Pseudolymphoma | 1 | 2010 | 4 | 0.390 |
Why?
| BRCA2 Protein | 1 | 2010 | 23 | 0.380 |
Why?
| Prednisolone | 3 | 2020 | 57 | 0.380 |
Why?
| Mutation, Missense | 1 | 2010 | 117 | 0.370 |
Why?
| Retrospective Studies | 7 | 2021 | 6459 | 0.370 |
Why?
| Drug Overdose | 1 | 2011 | 154 | 0.340 |
Why?
| Treatment Outcome | 4 | 2020 | 5612 | 0.310 |
Why?
| Diagnosis, Differential | 3 | 2020 | 1141 | 0.310 |
Why?
| Drug Therapy, Combination | 2 | 2020 | 426 | 0.260 |
Why?
| Heterozygote | 2 | 2023 | 96 | 0.250 |
Why?
| Follow-Up Studies | 3 | 2021 | 2390 | 0.250 |
Why?
| Young Adult | 6 | 2021 | 4318 | 0.250 |
Why?
| Muscle, Skeletal | 1 | 2010 | 847 | 0.250 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2023 | 58 | 0.220 |
Why?
| Adenosine Triphosphatases | 1 | 2022 | 90 | 0.210 |
Why?
| Atrophy | 1 | 2022 | 40 | 0.210 |
Why?
| Semaphorins | 1 | 2021 | 3 | 0.210 |
Why?
| Magnetic Resonance Imaging | 3 | 2018 | 1616 | 0.210 |
Why?
| Patient Care Planning | 1 | 2022 | 79 | 0.200 |
Why?
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2021 | 4 | 0.200 |
Why?
| Cell Adhesion Molecules | 1 | 2021 | 87 | 0.200 |
Why?
| Receptors, Cell Surface | 1 | 2021 | 130 | 0.190 |
Why?
| Cohort Studies | 2 | 2018 | 1546 | 0.190 |
Why?
| Introns | 2 | 2018 | 49 | 0.190 |
Why?
| Muscle Cramp | 1 | 2020 | 5 | 0.190 |
Why?
| Adult | 7 | 2022 | 14207 | 0.180 |
Why?
| Injections, Spinal | 1 | 2019 | 19 | 0.180 |
Why?
| Flavoproteins | 1 | 2019 | 8 | 0.180 |
Why?
| Palliative Care | 1 | 2022 | 188 | 0.180 |
Why?
| Phosphoric Monoester Hydrolases | 1 | 2019 | 24 | 0.180 |
Why?
| Recovery of Function | 1 | 2021 | 222 | 0.180 |
Why?
| Hand Strength | 1 | 2019 | 32 | 0.180 |
Why?
| Facial Paralysis | 1 | 2020 | 24 | 0.180 |
Why?
| Physical Endurance | 1 | 2019 | 49 | 0.180 |
Why?
| Muscle Weakness | 1 | 2020 | 46 | 0.180 |
Why?
| Age of Onset | 1 | 2019 | 117 | 0.180 |
Why?
| Steroids | 1 | 2019 | 55 | 0.180 |
Why?
| Neurologic Examination | 1 | 2019 | 76 | 0.180 |
Why?
| Genetic Therapy | 1 | 2020 | 121 | 0.170 |
Why?
| Abnormalities, Multiple | 2 | 2011 | 162 | 0.170 |
Why?
| Membrane Proteins | 1 | 2022 | 389 | 0.170 |
Why?
| Scoliosis | 1 | 2019 | 59 | 0.170 |
Why?
| Aminomethyltransferase | 1 | 2018 | 1 | 0.170 |
Why?
| Hyperglycinemia, Nonketotic | 1 | 2018 | 5 | 0.170 |
Why?
| Hyperammonemia | 1 | 2018 | 18 | 0.170 |
Why?
| Spinal Fusion | 1 | 2019 | 71 | 0.170 |
Why?
| Age Factors | 3 | 2018 | 1199 | 0.170 |
Why?
| Lumbosacral Region | 1 | 2018 | 11 | 0.170 |
Why?
| X-Rays | 1 | 2018 | 57 | 0.160 |
Why?
| Activities of Daily Living | 1 | 2019 | 204 | 0.160 |
Why?
| Neuraminidase | 1 | 2018 | 4 | 0.160 |
Why?
| Mucolipidoses | 1 | 2018 | 4 | 0.160 |
Why?
| Anti-Inflammatory Agents | 1 | 2019 | 175 | 0.160 |
Why?
| Pons | 1 | 2017 | 19 | 0.150 |
Why?
| Methylprednisolone | 1 | 2017 | 38 | 0.150 |
Why?
| Brain Stem | 1 | 2017 | 46 | 0.150 |
Why?
| Prevalence | 1 | 2020 | 1025 | 0.150 |
Why?
| Disease Progression | 1 | 2019 | 915 | 0.140 |
Why?
| Cross-Sectional Studies | 2 | 2019 | 1696 | 0.140 |
Why?
| Quality of Life | 1 | 2022 | 924 | 0.130 |
Why?
| T-Lymphocytes | 1 | 2017 | 374 | 0.130 |
Why?
| Aged | 3 | 2021 | 10060 | 0.120 |
Why?
| RNA, Messenger | 1 | 2018 | 1203 | 0.120 |
Why?
| Chronic Disease | 1 | 2017 | 614 | 0.120 |
Why?
| Antibodies | 2 | 2012 | 178 | 0.120 |
Why?
| Kv1.1 Potassium Channel | 1 | 2013 | 2 | 0.120 |
Why?
| Middle Aged | 3 | 2021 | 13082 | 0.110 |
Why?
| Dipeptides | 1 | 2012 | 20 | 0.110 |
Why?
| Aspartic Acid | 1 | 2012 | 48 | 0.110 |
Why?
| Folic Acid Deficiency | 1 | 2012 | 43 | 0.110 |
Why?
| Folate Receptor 1 | 1 | 2012 | 24 | 0.110 |
Why?
| Ear | 1 | 2011 | 20 | 0.100 |
Why?
| Prefrontal Cortex | 1 | 2012 | 89 | 0.100 |
Why?
| Immune System Diseases | 1 | 2011 | 10 | 0.100 |
Why?
| Facies | 1 | 2011 | 35 | 0.100 |
Why?
| Hypoparathyroidism | 1 | 2011 | 11 | 0.100 |
Why?
| Eye Abnormalities | 1 | 2011 | 22 | 0.100 |
Why?
| Epilepsies, Partial | 1 | 2011 | 13 | 0.100 |
Why?
| Platybasia | 1 | 2011 | 6 | 0.100 |
Why?
| Nose | 1 | 2011 | 42 | 0.100 |
Why?
| Social Behavior | 1 | 2011 | 83 | 0.100 |
Why?
| Frontal Lobe | 1 | 2011 | 56 | 0.100 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 121 | 0.100 |
Why?
| Child Behavior | 1 | 2011 | 114 | 0.100 |
Why?
| Glycogen Storage Disease Type III | 1 | 2010 | 1 | 0.100 |
Why?
| Glycogen Debranching Enzyme System | 1 | 2010 | 2 | 0.100 |
Why?
| Anxiety Disorders | 1 | 2011 | 138 | 0.100 |
Why?
| Cervical Vertebrae | 1 | 2011 | 65 | 0.090 |
Why?
| Infant, Newborn | 1 | 2018 | 2923 | 0.090 |
Why?
| Genetic Heterogeneity | 1 | 2010 | 22 | 0.090 |
Why?
| Cleft Palate | 1 | 2011 | 72 | 0.090 |
Why?
| Genetic Predisposition to Disease | 1 | 2013 | 570 | 0.090 |
Why?
| Syndrome | 1 | 2010 | 253 | 0.090 |
Why?
| Brain Mapping | 1 | 2011 | 250 | 0.090 |
Why?
| Cognition Disorders | 1 | 2011 | 240 | 0.090 |
Why?
| United States | 1 | 2020 | 5208 | 0.090 |
Why?
| Lymph Nodes | 1 | 2010 | 284 | 0.080 |
Why?
| Myocardium | 1 | 2010 | 443 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 1 | 2011 | 1476 | 0.070 |
Why?
| Skin | 1 | 2010 | 469 | 0.070 |
Why?
| Exercise | 1 | 2010 | 552 | 0.070 |
Why?
| Heart Defects, Congenital | 1 | 2011 | 608 | 0.060 |
Why?
| Azo Compounds | 1 | 2022 | 12 | 0.050 |
Why?
| Electrodiagnosis | 1 | 2021 | 14 | 0.050 |
Why?
| Genetic Association Studies | 1 | 2021 | 136 | 0.050 |
Why?
| Pyrimidines | 1 | 2022 | 196 | 0.050 |
Why?
| Homozygote | 1 | 2018 | 60 | 0.040 |
Why?
| Signal Transduction | 1 | 2021 | 1752 | 0.030 |
Why?
| Flurothyl | 1 | 2013 | 1 | 0.030 |
Why?
| Kindling, Neurologic | 1 | 2013 | 3 | 0.030 |
Why?
| Mice, Mutant Strains | 1 | 2013 | 84 | 0.030 |
Why?
| Aged, 80 and over | 1 | 2021 | 3431 | 0.030 |
Why?
| Animals, Newborn | 1 | 2013 | 396 | 0.030 |
Why?
| Protons | 1 | 2012 | 81 | 0.030 |
Why?
| Hippocampus | 1 | 2013 | 242 | 0.030 |
Why?
| Chi-Square Distribution | 1 | 2012 | 318 | 0.030 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2012 | 255 | 0.020 |
Why?
| Anisotropy | 1 | 2011 | 64 | 0.020 |
Why?
| Autoantibodies | 1 | 2011 | 135 | 0.020 |
Why?
| Drug Resistance | 1 | 2011 | 75 | 0.020 |
Why?
| Video Recording | 1 | 2011 | 90 | 0.020 |
Why?
| Neuropsychological Tests | 1 | 2012 | 363 | 0.020 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2011 | 128 | 0.020 |
Why?
| Exons | 1 | 2010 | 105 | 0.020 |
Why?
| Sequence Homology, Amino Acid | 1 | 2010 | 180 | 0.020 |
Why?
| Emotions | 1 | 2011 | 170 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 2010 | 767 | 0.020 |
Why?
| Cognition | 1 | 2011 | 350 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2010 | 980 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2013 | 2001 | 0.020 |
Why?
| Case-Control Studies | 1 | 2011 | 1229 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2013 | 1647 | 0.020 |
Why?
| Mice | 1 | 2013 | 6428 | 0.010 |
Why?
| Animals | 1 | 2013 | 14409 | 0.010 |
Why?
|
|
Veerapandiyan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|